Kuijpers Kiki W K, Andersson Karl, Winkvist Maria, Niesters Marieke, van Velzen Monique, Nyberg Fred, Dahan Albert, Hämäläinen Markku D
Department of Anesthesiology, Leiden University Medical Center, Leiden, Netherlands.
Skillsta Teknik Design och Kvalitet AB, Vänge, Sweden.
Front Neurosci. 2025 Jan 7;18:1492246. doi: 10.3389/fnins.2024.1492246. eCollection 2024.
It is known that illicit and prescribed drugs impact pupil size, eye movement and function. Still, comprehensive quantitative evaluations under known ambient light conditions are lacking, when smartphones are used for monitoring.
In this clinical study (NCT05731999), four medicinal products with addiction risks were administered to 48 subjects (18-70 years old, all with informed consent, 12 subjects per drug). Videos captured by smartphones at ~50 lux and ~ 500 lux documented the eye's reaction before and after controlled intake of single doses of oral oxycodone (20 mg), lorazepam (2 mg), lisdexamphetamine (70 mg) and inhaled cannabis flos (65 mg with 22% THC) over a 5-h test period. Data from three observational tests, non-convergence (NC, ability to cross the eyes), nystagmus (NY), and pupillary light reflex (PLR) were converted into 24 key features that represent different eye characteristics.
Of the acquired data, 87-97% produced key features. At peak drug plasma concentration, oxycodone constricted pupils ( < 0.001); lorazepam induced non-convergence ( < 0.001); lisdexamphetamine induced dilated pupils ( < 0.001), irrespective of ambient light conditions. Inhaled cannabis induced miosis ( = 0.05 at ~50 lux, = 0.10 at ~500 lux), a reduced light-induced amplitude ( = 0.003 at ~50 lux, = 0.3 at ~500 lux) and redness of the sclerae ( = 0.14 at ~50 lux, = 0.007 at ~500 lux). The drug effect lasted at least 5 h ( < 0.005) except for inhaled cannabis (2-3 h, < 0.05).
The ocular response to oxycodone, lorazepam, lisdexamphetamine and cannabis, as measured under controlled light conditions using a smartphone-based assessment, demonstrated distinct and readily distinguishable patterns for each substance.
Identifier, NTC05731999.
已知非法药物和处方药会影响瞳孔大小、眼球运动及功能。然而,在使用智能手机进行监测时,缺乏在已知环境光照条件下的全面定量评估。
在这项临床研究(NCT05731999)中,对48名受试者(年龄在18至70岁之间,均签署知情同意书,每种药物12名受试者)施用了四种具有成瘾风险的药品。在约50勒克斯和约500勒克斯环境光照下,由智能手机拍摄的视频记录了在5小时测试期内单次口服羟考酮(20毫克)、劳拉西泮(2毫克)、赖右苯丙胺(70毫克)和吸入大麻(含65毫克及22%四氢大麻酚)前后眼睛的反应。来自三项观察性测试的数据,即非集合(NC,双眼交叉能力)、眼球震颤(NY)和瞳孔对光反射(PLR),被转换为代表不同眼部特征的24个关键特征。
在获取的数据中,87%至97%产生了关键特征。在药物血浆浓度峰值时,羟考酮使瞳孔收缩(<0.001);劳拉西泮诱发非集合(<0.001);赖右苯丙胺诱发瞳孔扩张(<0.001),与环境光照条件无关。吸入大麻诱发瞳孔缩小(在约50勒克斯时P = 0.05,在约500勒克斯时P = 0.10)、光诱导幅度降低(在约50勒克斯时P = 0.003,在约500勒克斯时P = 0.3)以及巩膜发红(在约50勒克斯时P = 0.14,在约500勒克斯时P = 0.007)。除吸入大麻外(2至3小时,P < 0.05),药物效果持续至少5小时(P < 0.005)。
在可控光照条件下使用基于智能手机的评估方法所测量的眼睛对羟考酮、劳拉西泮、赖右苯丙胺和大麻的反应,显示出每种物质独特且易于区分的模式。
标识符,NTC05731999。